. 2020 Jul 4;13(6):1260–1270. doi: 10.1111/cts.12814

Table 4.

Summary of TEAEs ^a (ITT‐S population) (N = 52)

Participants with ≥ 1 TEAE, ^a n (%) m	Maribavir 100 mg ^b (n = 51)	Maribavir 1,200 mg ^c (n = 51)	Moxifloxacin (N = 52)	Placebo (N = 52)
All TEAEs	19 (37) 29	43 (84) 71	11 (21) 20	8 (15) 13
TEAEs related to study drug ^a , ^d	14 (28) 14	41 (80) 41	2 (4) 2	1 (2) 1
Serious TEAEs	0	0	0	0
Deaths	0	0	0	0

ITT, intent‐to‐treat; ITT‐S, ITT safety; TEAE, treatment‐emergent AE.

^{^a}

TEAEs: All adverse events that started on or after the first dose of the study drug (day 1 of treatment period 1) or increased in severity after the first dose of the study drug. Events that had an onset date during the washout period were counted under the previous treatment period.

^{^b}

One participant was discontinued due to a TEAE of an upper respiratory infection and did not receive maribavir 100 mg.

^{^c}

One participant did not return for the fourth treatment period and did not receive maribavir 1,200 mg.

^{^d}

Related adverse events included events with the relationship to the study drug recorded as possible, probable, or definite, and events with an unknown or unrecorded relationship.